Conmed (CNMD) Q1 2026 Earnings Report Shows Mixed Results
Conmed (CNMD) reported Q1 2026 earnings with total sales of $317 million, a 1.3% year-over-year decline, primarily due to the exit of its gastrointestinal product line. Organic sales growth was 2.1% year-over-year, with the Orthopedics segment showing 4.5% growth in constant currency, while the General Surgery segment declined 8.5% in constant currency.
Topics: clinical studies earnings report product line exit regulatory developments sales growth segment performance